Investor Update and Notice of Investor Briefing
Released
Released
Announcement PDF
ASX / MEDIA ANNOUNCEMENT
INVESTOR UPDATE
Brisbane, Australia and Delaware, United States, 8 November 2017: Invion Limited (ASX: IVX) is pleased
to provide an Investor Update to the market, following the announcement on 31 August 2017 of a
strategic transaction with The Cho Group, and the lodgement on 30 October 2017 of the Company’s
Notice of Annual General Meeting.
The attached Investor Update provides information on the Strategic Transaction with The Cho Group to
develop and commercialise the New Generation PhotoDynamic Therapy, Photosoft, targeted to the
treatment of solid cancers.
Investor Briefing: An Investor Briefing will be held at 2.00pm (Brisbane time) on Monday 13 November.
Investors are invited to pre-register for the Briefing. To receive a calendar invite and pin number for fasttrack access to the call, please follow this link:
https://services.choruscall.com.au/diamondpass/buchan-639912-invite.html
-----FOR MORE INFORMATION CONTACT: Interim Executive Chair: Dr Greg Collier. P: 07 3295 0500
investor@inviongroup.com
Invion Limited ABN 76 094 730 417
GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com
INVION
INVESTOR
UPDATE
Strategic Transaction with The Cho Group to develop and
commercialise the New Generation PhotoDynamic Therapy,
Photosoft™, targeted to the treatment of solid cancers
INVION STRATEGY IN 2017
AIM:
OUTCOME:
Identify and pursue opportunities to
reshape and enhance the company’s
pipeline and business growth
Licence to develop and commercialise
Photosoft™ for the treatment of cancers
Agreement that provides non-dilutive
funding for asset development
STRATEGIC
TRANSACTION
WITH THE
CHO GROUP
R&D Services Agreement:
Invion will conduct clinical
development of Photosoft™ globally,
leveraging the Company’s expertise.
The Cho Group will provide nondilutive funding for R&D and clinical
trials as part of a global development
strategy for the asset
1
3
2
Exclusive Distribution
and Licence Agreement:
Invion has exclusivity in Australia and
New Zealand to commercialise and
distribute Photosoft™ for the treatment
of cancers. Licence value $5.5M at
$0.002 per share
Underwriting
Agreement:
The Cho Group will fully
underwrite Rights Issue
to raise up to $2.5M
WHAT IS PHOTO DYNAMIC
THERAPY (PDT)?
Use of light to destroy cancerous
cells or other abnormal tissue
When exposed to specific wavelengths of
light, photosensitizing agents produce a
form of oxygen that causes destruction of
nearby cells without damaging nearby tissue
Wavelength determines how far
the light can travel into the body
HOW PDT
WORKS
1
2
3
4
Photosensitizing
agent is taken (by
mouth) or given
(intravenously)
The agent circulates through
the body and concentrates at
the site of the tumour
Light of specific wavelengths is
shone on the body which
activates the reaction in the
tumour
The tumour is
selectively destroyed
PDT IN
PRACTICE
PDT IS USUALLY
PERFORMED AS AN
OUTPATIENT PROCEDURE
There are a number of clinics throughout
Australia that offer PDT therapy for the
treatment of superficial skin cancers,
and sunspots, including solar keratoses
PDT may be repeated and may be used
with other therapies, such as surgery,
radiation therapy, or chemotherapy
PDT is non-invasive and has lower
negative side effects than other
therapies
HISTORY OF
PHOTODYNAMIC THERAPY
1903
1904
1925
1942
1958
Nobel Prize
N. Finsen:
Light therapy
for skin
conditions
Von Tappeiner:
PD reaction first
shown
Nobel Prize
H. Fischer:
Porphyrins
description
Porphrins:
First used in
treatments
Light Bed therapy
for Neonatal
Jaundice
1971-85
Dougherty:
Photofrin
therapy
Russian and
Chinese PDT
developments
NASA & RSA
1990
2006
Windahl et al.
(Denmark): PDT
for local
prostate
cancer
Moore &
Emberton
(England):
Interstitial
prostate PDT
PDT
therapy became
‘mainstream’ in
1995 with the FDA
approval of Photofrin
Ⓡ(porfimer sodium)
for treatment
of esophageal
cancer
Variants of
PhotofrinⓇ
were
subsequently
developed in
clinical trials
HOWEVER FIRST
GENERATION PDT
HAD PROBLEMS:
FIRST
GENERATION
PHOTOSENSITIZERS
Tended to remain
in the body for
long periods
Fat solubility
Does not absorb
longer
wavelengths so
treatment depth
was limited
Leading
to limited
effectiveness
and
applicability
Largely
chlorophyll
based
Water soluble
with good
tissue
distribution
SECOND
GENERATION
PHOTOSENSITIZERS
BETTER
TUMOR
SPECIFICITY
Strong absorption
and longer
wavelengths
allowing deeper
penetration of
tissues
Low circulation
times so patients
are not left
vulnerable to
sunlight damage
Different
chemistry
NEW WAVE OF INTEREST
WITH TOOKAD
STEBA BIOTECH CONDUCTED PH III IN 208
PATIENTS WITH LOW-RISK PROSTATE CANCER:
participants who had
disease progression
at month 24:
TOOKAD
GROUP
ACTIVE
SURVEILLANCE
GROUP (P<0·0001)
28%
58%
“Localised, low-risk prostate cancer can be
treated in a way that not only preserves
genitourinary function but also results in a
lower progression rate, a greater chance of
being declared disease-free, and a
reduction in need for whole-gland radical
therapy in the form of surgery or
radiotherapy compared with active
surveillance”
May allow more men to consider a tissuepreserving approach and defer or avoid
radical therapy.
men who had a
negative prostate
biopsy result at 24
months post treatment:
49%
14%
Tookad submitted for EMA approval, 2017
Azzouzi, Abdel-Rahmène et al. (2016) Padeliporfin vascular-targeted photodynamic therapy versus
active surveillance in men with low-risk prostate cancer. The Lancet Oncology (18:2 181–191)
NEW GENERATION
PHOTO DYNAMIC
THERAPY: PHOTOSOFT™
Invion to in-licence asset based on
patented PDT agent Photosoft™
Targeted to address limitations of
1st Generation PDT therapies
Uses a laser light activation method based on a
short, pulsating Near Infrared (NIR) wavelengths
High photodynamic efficiency combined with NIR
peaks of absorption
NIR light therapy allows more effective whole-ofbody systemic treatment that can target
circulating cancer cells as well as deeply seated
tumours
PHOTOSOFT™
Chlorophyll-based PDT photosensitiser
Complex of chlorin and chlorophyllin
ACTIVATES AT MULTIPLE
SENSITIVITY RANGES ACROSS
A BROAD SPECTRUM
CURRENTLY AVAILABLE
THERAPIES
PHOTOSOFT™
ADVANTAGES
PHOTOSOFT™
1
Activation at multiple ranges allows deeper
tissue penetration for the light source
Water soluble
Good bioavailability – can be administered
sublingually and intravenously
Chlorin-e6 and Chlorophyllin-A are used
Positive immune response demonstrated in
Phase I clinical trials
2
1ST GENERATION VS PHOTOSOFT™
1ST GENERATION PDT
PHOTOSOFT™
CLEARANCE
TIME
2 to 3 months clearance time. This causes extreme light sensitivity
and patients are generally required to stay indoors.
Fast body clearance time from normal cells and tissue structures as well
as organs. Combined with high cancer cell selectivity allows patients to
safely walk in the sunlight.
SELECTIVITY
FOR CANCER
CELLS
Low cancer cell selectivity therefore binds / penetrates non- cancer
cells. Treatment requires endoscopic intervention with laser light
directed through a fibre optic toward the tumour to avoid healthy cells.
Highly selective only accumulating in cancer cells therefore the light
activation can be safely provided over the whole body to treat every
area affected by cancer.
TOXICITY
Some 1st generation PDT agents are derived from synthetic materials
that are toxic.
Photosoft is chlorophyll-based, derived form plants.
DEPTH OF
LIGHT
PENETRATION
Limited application and only used for surface tumours as the agent
activation light is able to penetrate between 0.5 and 3 cm depth.
Photosoft is activated with specific high frequency light able to penetrate
through solid tissues and bone to deeply seated tumours.
SINGLET
OXYGEN YIELD
Generate a low level of singlet oxygen release so effectiveness to kill
cancer cells is limited.
Photosoft has photodynamic efficiency capable of producing a high level
of singlet oxygen, resulting in more effective cancer cell damage and
death.
CANCER CELL
PENETRATION
Oil based photo-sensitizer agents have low membrane permeation
properties causing them to be weakly absorbed across the cell
membrane.
Photosoft possesses both hydrophilic (water-loving) and lipophylic (fatloving) properties enabling the agent to penetrate cancer cell membrane
and accumulate in high concentration inside the cancer cell increasing
damage and cell death.
LIMITATION
LOCALISED
PROSTATE CANCER:
THE STATE OF PLAY
INCREASING NUMBERS OF MEN ARE
CHOOSING ACTIVE SURVEILLANCE
OVER SURGERY OR RADIOTHERAPY
BECAUSE OF THE RISKS OF THESE
TREATMENTS
Active surveillance was ~6% of US patients 15 years ago,
now 40%
Surgery and radiotherapy are radical treatments associated
with urinary incontinence (9-18% over 15 years), erectile
dysfunction (87-94%) and poor bowel function (22-36%)
Over 20,000 men are diagnosed each year in
Australia and New Zealand at estimated lifetime cost
of A$26,000 p.a. = large market opportunity
References: Nat Rev Urol. 2016 Apr; 13(4): 205–215; N Engl J Med. 2013 Jan 31;368(5):436-45; Prostate Cancer Foundation of Australia
EARLY STUDIES OF PHOTOSOFT™
CONDUCTED IN AUSTRALIA
PHASE I | PROSTATE CANCER
2013
2017
o Photosoft™ was administered to 68 prostate cancer patients by
Urologist Donald Murphy and collaborators
o A second Phase I was completed by Donald Murphy in
collaboration with Monash University
o Results for 26 patients that had been treated for >6 months were
reported at the Urological Society of Australia and New Zealand
meeting in Melbourne in April 2013
o Participants had localised treatment-naïve prostate cancer or
were patients with local relapse
o Half of patients had stable to decreasing PSA and half increasing
PSA, while prostate size generally fell on assessment using
diagnostic imaging
o PSA levels were checked at three months post-treatment and
found four of seven first-line patients registering stable PSA.
None of the three relapse patients registered stable PSA.
o Photosoft™ was safe and well-tolerated
o A global reduction in prostate size was noted across the primary
treatment group
o A proteomics analysis of protein samples found in the urine of
the patients found various immune-related biomarkers were
upregulated, with high statistical significance (p<0.001)
A NEW WAVE:
IMMUNOTHERAPY
AND PDT
2013
Immune
response is
important in the
control of tumour
growth
2017
o Photosoft was administered to 68 prostate cancer patients by
Urologist Donald Murphy and collaborators
o A second Phase I was completed by Donald Murphy in
collaboration with Monash University
o Results for 26 patients that had been treated for >6 months were
reported at the Urological Society of Australia and New Zealand
meeting in Melbourne in April 2013
o Participants had localised treatment-naïve prostate cancer or
were patients with local relapse
o Half of patients had stable to decreasing PSA and half increasing
PSA, while prostate size generally fell on assessment using
diagnostic imaging
o Photosoft was safe and well-tolerated
Research in
In vivo evidence
PDT
space
o PSA levels were checked the
at three
months
post-treatment and
exists that
found four of seven first-line
patients
registering stable PSA.
is
increasingly
immunotherapy
None of the three relapse patients registered stable PSA.
considering the
and PDT could
o A global reduction in prostate
size was noted across the primary
immunological
work well together
treatment group
implications
o A proteomics analysis of protein samples found in the urine of
the patients found various immune-related biomarkers were
upregulated, with high statistical significance (p<0.001)
References: Neoplasma. 2010;57(2):184-8; Photochem Photobiol Sci. 2011 May;10(5):681-8. doi: 10.1039/c0pp00315h. Epub 2011 Jan 24
PHASE I PROSTATE
CANCER DATA
86 proteins relating
to immune responses
were observed
Proteins relating
to certain immune
response pathways
are enriched and
were significantly
over-represented
within the dataset
ADVANTAGES OF NGPDT
AND PHOTOSOFT™
The immune response observed by Murphy in the Phase I
provides potential advantages over other water-soluble
PDT therapies such as TookadⓇ
There is a growing body of knowledge that PDT has the
potential to generate an anti-cancer immune response
TookadⓇ Ph III success and EMA submission brings PDT
into the mainstream via wider research, medical application
and potential commercial success
PDT therapies target early-state treatment as non-invasive
and repeatable
TARGETS
Skin cancers including
melanoma, squamous
cell carcinoma & basal
cell carcinoma
Lung cancer
Prostate or
Ovarian cancer
PDT THERAPIES
TARGET
EARLY-STAGE
TREATMENT AS
NON-INVASIVE
AND REPEATABLE
Establish Scientific
Advisory Board,
and timing/ costs of
Phase II/ III clinical
trials in prostate
cancer leading to
approval
submissions
Explore short term
opportunities for
treatment of skin
cancers and other
disorders
Develop ovarian
cancer strategy as
the next clinical
opportunity for
Photosoft™
FIRST STEPS:
FUNDED WITH
NON-DILUTIVE
CAPITAL
ACQUISITION/
LICENSING
OPPORTUNITIES
INV103 (Cpn10)
INV102 (Nadolol)
INV104 (Zafirlukast)
Current assets have completed programmed clinical
development
Management remains committed to licensing the
assets
MANAGEMENT
TEAM
CURRENT
Dr Greg Collier
Interim Executive
Chair
Dr Mitchell Glass
(Invion, Inc).
Chief Medical
Officer
Melanie Farris
Head of
Operations and
Company
Secretary
MANAGEMENT
TEAM
POST-CURRENT
TRANSACTION
Mr Thian Chew
Dr Greg Collier
Non-Executive
Chairman
Chief Executive
Officer
Dr Mitchell Glass
(Invion, Inc).
Chief Medical
Officer
Melanie Farris
Head of
Operations and
Company
Secretary
Other
Board changes
anticipated to
occur in 2018
COMPANY SNAPSHOT AND
IMPACT OF TRANSACTION
The effect of the proposed transaction on the
capital structure of the Company
Overall ownership structure of the Company after
completion of the Underwritten Rights Issue
Number of
Shares
Percentage of
issued capital
Shares on issue at the date of the Notice of Meeting
1,455,965,273
26.69%
Shares to be issued under the Exclusive
Distribution and Licence Agreement (resolution 7)
2,750,000,000
Shares to be issued under the Underwritten
Rights Issue (resolution 8)
TOTAL
Shareholder
Number of
Shares
Percentage
interest
50.40%
All existing Shareholders other than The Cho Group
1,604,725,067
29.41%
1,250,000,000
22.91%
The Cho Group and Polar Ventures
3,851,240,206
70.59%
5,455,965,273
100%
TOTAL
5,455,965,273
100%
IMPORTANT
DATES:
INDICATIVE
TIMETABLE
Monday, 30 October 2017
Monday, 13 November
Notice of Meeting lodged with ASX
and dispatched to Shareholders
Invion Investor Session
Thursday, 30 November 2017
Date of Annual General Meeting
Thursday, 7 December 2017
Issue of Shares under the
Exclusive Distribution and Licence
Agreement
Monday, 11 December 2017
Consolidation to take effect
First quarter 2018
Announce Underwritten
Rights Issue
RESOURCE
SLIDES
WHAT IS PHOTODYNAMIC
THERAPY?
Photodynamic therapy (PDT) was developed at
Roswell Park Cancer Institute (RPCI) in the late
1970s by Thomas Dougherty, PhD
PDT is a treatment that uses a light sensitive drug
– a photosensitiser - and non-thermal visible red
light, typically generated by a laser
When photosensitisers are exposed to a specific
wavelength of light, they produce a form of oxygen
that causes an almost immediate destruction of
nearby cells without permanently damaging
surrounding tissue
Each photosensitising agent is activated by light of a
specific wavelength. Wavelength determines how far
the light can travel into the body
https://www.roswellpark.org/patients/treatment-services/innovative-treatments/photodynamic-therapy
https://www.cancer.gov/about-cancer/treatment/types/surgery/photodynamic-fact-sheet
PDT MECHANISM
OF ACTION
PHOTODYNAMIC THERAPY (PDT)
uses non-toxic photosensitisers and harmless visible light in
combination with oxygen to produce cytotoxic reactive oxygen
species that kill malignant cells by apoptosis and/or necrosis,
shut down the tumour microvasculature and stimulate the host
immune system. In contrast to surgery, radiotherapy and
chemotherapy that are mostly immunosuppressive, PDT
causes acute inflammation, expression of heat-shock proteins,
invasion and infiltration of the tumour by leukocytes, and might
increase the presentation of tumour-derived antigens to T
cells.
Castano et al. 2006. ‘Photodynamic therapy and anti-tumour immunity’. Nat Rev Cancer Jul;6(7):535-45.
RESEARCH OUTPUT: MD ANDERSON CENTRE
Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong
survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue
toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired
resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this
treatment make it a valuable therapeutic option for combination treatments. With a number of recent
technological improvements, PDT has the potential to become integrated into the mainstream of cancer
treatment.
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., ... Golab, J.
(2011). Photodynamic therapy of cancer: An update. CA Cancer Journal for Clinicians, 61(4), 250-281.
DOI: 10.3322/caac.20114
PDT IN
PRACTICE
The light used for PDT can come from a laser or other sources
o Laser light can be directed through fiber optic cables to
deliver light to areas inside the body. For example, a fiber
optic cable can be inserted through an endoscope into the
lungs or esophagus to treat cancer in these organs
o Other light sources include light-emitting diodes (LEDs),
which may be used for surface tumors, such as skin
cancer.
PDT is usually performed as an outpatient procedure
PDT may also be repeated and may be used with other
therapies, such as surgery, radiation therapy, or chemotherapy.
There are a number of clinics throughout Australia that offer PDT
therapy for the treatment of superficial skin cancers, and
sunspots, including solar keratoses.
https://www.cancer.gov/about-cancer/treatment/types/surgery/photodynamic-fact-sheet
COMPARABLE COMPANY:
PHOTOCURE
Norweigian specialty
pharmaceutical company
focusing on urology
and its Photocure
Technology® platform
Provides “important qualities
that enhance the properties
of photodynamic technology
for diagnosis and therapy.
Uniquely selective for
diseased cells, effective and
safe, minimally invasive”
US$77m
cap on Oslo Bors
Share your feedback
Discover